Journal Mobile Options
Table of Contents
Vol. 18, No. 1, 2004
Issue release date: July 2004
Cerebrovasc Dis 2004;18:8–15

Direct Medical Costs Attributable to Acute Myocardial Infarction and Ischemic Stroke in Cohorts with Atherosclerotic Conditions

Sloss E.M. · Wickstrom S.L. · McCaffrey D.F. · Garber S. · Rector T.S. · Levin R.A. · Guzy P.M. · Gorelick P.B. · Dake M.D. · Vickrey B.G.
Rand Corp., Santa Monica, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The cost of acute ischemic events in persons with established atherosclerotic conditions is unknown. Methods: The direct medical costs attributable to secondary acute myocardial infarction (AMI) or ischemic stroke among persons with established atherosclerotic conditions were estimated from 1995–1998 data on 1,143 patients enrolled in US managed care plans. Results: The average 180-day costs attributable to secondary AMI or stroke were estimated as USD 19,056 in the AMI cohort having a private insurance (commercial; n = 344), USD 16,845 in the AMI cohort having government insurance (Medicare, age ≧65 years; n = 200), USD 10,267 for stroke commercial (n = 108), USD 16,280 for stroke Medicare (n = 113), USD 15,224 for peripheral arterial disease commercial (n = 170), and USD 15,182 for peripheral arterial disease Medicare (n = 208). Conclusion: These estimates can be used to study the cost-effectiveness of interventions proven to reduce these secondary events.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA: Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901–906.

    External Resources

  2. Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S, Keren A: Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. Am J Cardiol 1997;80:1429–1433.
  3. Brass LM, Hartigan PM, Page WF, Concato J: Importance of cerebrovascular disease in studies of myocardial infarction. Stroke 1996;27:1173–1176.
  4. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339.
  5. Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF: Intermittent claudication: A risk profile from the Framingham Heart Study. Circulation 1997;96:44–49.
  6. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF: Lifetime cost of stroke in the United States. Stroke 1996;27:1459–1466.
  7. Taylor TN: The medical economics of stroke. Drugs 1997;54(suppl):S51–S57.
  8. Hay JW, Wittels EH, Gotto AM Jr: An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789–796.
  9. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L: Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409–414.
  10. Mantovani LG, Belisari A, Szucs TD: Captopril in the management of patients after acute myocardial infarctions: A cost-effectiveness analysis in Italy. Pharmacol Res 1998;37:345–351.
  11. Muls E, Van Ganse E, Closon MC: Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998;137(suppl):S111–S116.
  12. Marissal JP, Selke B, Lebrun T: Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics 2000;18:185–200.
  13. Wittels EH, Hay JW, Gotto AM Jr: Medical costs of coronary artery disease in the United States. Am J Cardiol 1990;65:432–440.
  14. Scott WG, White HD, Scott HM: Cost of coronary heart disease in New Zealand. N Z Med J 1993;106:347–349.
  15. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC: Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110–1115.
  16. Topol EJ, Ellis SG, Cosgrove DM, Bates ER, Muller DW, Schork NJ, Schork MA, Loop FD: Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation 1993;87:1489–1497.
  17. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB: Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 1997;336:92–99.
  18. Taylor GJ, Mikell FL, Moses HW, Dove JT, Katholi RE, Malik SA, Markwell SJ, Korsmeyer C, Schneider JA, Wellons HA: Determinants of hospital charges for coronary artery bypass surgery: The economic consequences of postoperative complications. Am J Cardiol 1990;65:309–313.
  19. SAS Institute: SAS OnlineDoc®, version 8. Cary, SAS Institute, 1999.
  20. Agency for Healthcare Research and Quality: Clinical Classifications Software (CCS), 1999. Available via
  21. Bang H, Tsiatis AA: Estimating medical costs with censored data. Biometrika 2000;82:329–343.
  22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  23. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, Chapman & Hall, 1993.
  24. Charles ED, Wayne JB, Oberman A, Reed BA, Haynie C, Kouchoukos NT, Rogers WJ, Russell RO: Costs and benefits associated with treatment for coronary artery disease. Circulation 1982;66(5 Pt 2):III87–III90.
  25. Ellis SG, Brown KJ, Ellert R, Howell GL, Miller DP, Flowers NM, Ott PA, Keys T, Loop FD, Topol EJ: Cost of cardiac care in the three years after coronary catheterization in a contained care system: Critical determinants and implications. J Am Coll Cardiol 1998;31:1306–1313.
  26. Ellis SG, Miller DP, Brown KJ, Omoigui N, Howell GL, Kutner M, Topol EJ: In-hospital cost of percutaneous coronary revascularization: Critical determinants and implications. Circulation 1995;92:741–747.
  27. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor D, Wallace AG, Mark DB: Resource use and cost of initial coronary revascularization: Coronary angioplasty versus coronary bypass surgery. Circulation 1990;82(5 Suppl):IV208–IV213.
  28. Ray GT, Collin F, Lieu T, Fireman B, Colby CJ, Quesenberry CP, Van Den Eden SK, Selby JV: The cost of health conditions in a health maintenance organization. Med Care Res Rev 2000;57:92–109.
  29. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM: Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629–635.
  30. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB: Discordance of databases designed for claims payment versus clinical information systems: Implications for outcomes research. Ann Intern Med 1993;119:844–850.
  31. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, Krumholz HM, Vogel RA: Quality of care for Medicare patients with acute myocardial infarction: A four state pilot study from the cooperative cardiovascular project. JAMA 1995;273:1509–1514.
  32. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L: Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115–121.
  33. Fisher ES, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, Hsia DC: The accuracy of Medicare’s hospital claims data: Progress has been made, but problems remain. Am J Public Health 1992;82:243–248.
  34. Iezzoni LI, Burnside S, Sickles L, Moskowitz MA, Sawitz E, Levine PA: Coding of acute myocardial infarction: Clinical and policy implications. Ann Intern Med 1988;109:745–751.
  35. Benesch C, Witter DM, Wilder AL, Duncan PW, Samsa GP, Matchar DB: Inaccuracy of the International Classification of Disease (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. Neurology 1997;49:660–664.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50